Trial Profile
Exploratory Study of Genetic Factors Related to the Inhibitory Effect of Tolvaptan on Increased Kidney Volume in Patients with Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2019
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Otsuka Pharmaceutical
- 25 Sep 2019 Status changed from not yet recruiting to completed.
- 03 Apr 2018 New trial record